Am J Cardiol. 2020 Aug 27:S0002-9149(20)30897-3. doi: 10.1016/j.amjcard.2020.08.040. Online ahead of print.
Since the modified CHA2DS2VASC (M-CHA2DS2VASc) risk score (RS) includes the prognostic risk factors for COVID-19; we assumed that it might predict in-hospital mortality and identify high risk patients at an earlier stage compared with troponin increase and neutrophil-lymphocyte ratio (NLR). We aimed to investigate whether M-CHA2DS2VASC RS is an independent predictor of mortality in patients hospitalized with COVID-19 and to compare its discriminative ability with troponin increase and NLR in terms of predicting mortality. 694 patients were retrospectively analyzed and divided into three groups according to M-CHA2DS2VASC RS which was simply created by changing gender criteria of the CHA2DS2VASC RS from female to male (Group 1, score 0-1 (n= 289); group 2, score 2-3 (n=231) and group 3, score ≥4 (n=174)). Adverse clinical events were defined as in-hospital mortality, admission to intensive care unit, need for high-flow oxygen and/or intubation. As the M-CHA2DS2VASC RS increased, adverse clinical outcomes were also significantly increased (Group 1, 3.8%; group 2, 12.6%; group 3, 20.8%; p<0.001 for in-hospital mortality). The multivariate logistic regression analysis showed that M-CHA2DS2VASC RS, troponin increase and NLR were independent predictors of in-hospital mortality (p=0.005, odds ratio 1.29 per scale for M-CHA2DS2VASC RS). In ROC analysis, comparative discriminative ability of M-CHA2DS2VASC RS was superior to CHA2DS2VASC RS score. Area under the curve (AUC) values for in-hospital mortality were 0.70 and 0.64 respectively. (AUCM-CHA2DS2-VASc vs. AUCCHA2DS2-VASc z test=3.56, p 0.0004) In conclusion, admission M-CHA2DS2VASc RS may be a useful tool to predict in-hospital mortality in patients with COVID-19.